leadf
logo-loader
viewIXICO PLC

IXICO teams up with NYU Langone Health to help in the quest to find a treatment for a rare degenerative neurological disorder

Dr Robin Wolz, senior vice president for science and innovation at IXICO, said: "This collaboration will help to accelerate the quest for new treatments for multiple system atrophy by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease"
xxxxxxx

IXICO PLC (LON:IXI) has said it is providing its neuroscience and data analytics expertise to a trial being run by NYU Langone Health to assess a new and potentially breakthrough use for a drug called Sirolimus.

Currently used to help prevent organ transplant rejection, the immunosuppressant is also able to slow the progression of multiple system atrophy (MSA) – a condition of the central nervous system that causes gradual damage to nerve cells in the brain.

The project with NYU Langone involves applying of IXICO's existing MSA analysis solutions to MRI retrospectively collected data from patients with the condition, as well as those that have dementia with Lewy Bodies, Parkinson's disease, and progressive supranuclear palsy.

The pair will also jointly develop a method to analyse susceptibility-weighted imaging, an MRI sequence that is particularly sensitive to compounds that distort the local magnetic field.

In a statement, Dr Robin Wolz, senior vice president for science and innovation at IXICO, said: "This collaboration will help to accelerate the quest for new treatments for multiple system atrophy by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease."

Quick facts: IXICO PLC

Price: 91 GBX

AIM:IXI
Market: AIM
Market Cap: £42.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Brexit bells set to ring this Christmas Eve

The market report with Katie Pilbeam. FTSE 100 headed to the Christmas break in good cheer on the growing possibility that a Brexit deal will be announced today. The news overshadowed reports of another mutant coronavirus strain and helped London’s blue-chip index rise 19 to 6,515. Yes,...

3 weeks, 3 days ago

2 min read